RCE.AU Recce Pharmaceuticals Ltd

Healthcare Pharmaceuticals Australian Securities Exchange
0.3600 AUD
Close of Oct 31, 2026
0.2650 0.7300
Market cap
AUD 110M
P/E
-
P/B
183.30x
ROE
-
Dividend yield
-
Fundamental score
0.2/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is RCE.AU undervalued?

Graham number

The Graham number of Recce Pharmaceuticals Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Recce Pharmaceuticals Ltd fundamental analysis

1 of 21 checks passed

ROE 0/2

ROE cannot be calculated: equity is negative or not reported.

ROA 0/1

Return on assets (-175.4%) is below the industry median (-8.9%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (42.8%) is below the industry median (42.8%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 0/2

Cash covers 0.3 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (183.3x) is above the industry median (2.0x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Recce Pharmaceuticals Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical…

Full company profile